To date, many studies on DCLK1 have supported it as a CSC marker for various cancers (Chandrakesan, et al., 2015a; Chandrakesan et al., 2017; Panneerselvam et al., 2020; Lorenzo et al., 2021) (Figure 1). This evidence concerns the gene DCLK1 and cancer.